@prefix dcterms: .
@prefix orcid: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix pav: .
@prefix rdf: .
@prefix xsd: .
@prefix rdfs: .
@prefix biolink: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: a np:Nanopublication;
np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo .
}
sub:assertion {
a biolink:DiseaseOrPhenotypicFeature;
rdfs:label "OCD" .
a biolink:ChemicalEntity;
rdfs:label "Fluoxetine" .
a biolink:DiseaseOrPhenotypicFeature;
rdfs:label "Obsessive Compulsive Disorder" .
a biolink:NamedEntity;
rdfs:label "adult " .
sub:_1 a rdf:Statement;
rdf:object ;
rdf:predicate biolink:treats;
rdf:subject .
}
sub:provenance {
sub:assertion prov:generatedAtTime "2022-09-16T17:18:27+00:00"^^xsd:dateTime;
prov:hadPrimarySource ;
prov:wasAttributedTo orcid:0000-0003-4727-9435;
prov:wasQuotedFrom "Fluoxetine is indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with Obsessive Compulsive Disorder (OCD)" .
biolink: pav:version "2.3.0" .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCTQs+mANCSHWhIW/YPio468UdGNHsPvADpjfaW8um/v2L4AoDIANginfoU65VNbPT5D0ADt1y0uFNne3VEMr9Y+I2HFaz6IKj+LdYMJk6VUf5WJoImRHIX6BZQwcUc22CbTBFYxvqvp3UmmHrCrhLIZjDSyutExK3tOTRoMDjGowIDAQAB";
npx:hasSignature "jmq43jenvsyPvm7tT6pmj/Rk6QJjqCfJHSqUXN9vB1raOfi3H+1oH/XjSnlY0j+0IRI2XTty7p3De02UBArVXQV1EAfgbulB1Ejf3ieUbJokyGY4J2QUOKD070UxMlBWCUG4K5rUn9cJK45H2KVqBCZvCHbx0XCorDxN2uRLZsU=";
npx:hasSignatureTarget this: .
this: dcterms:created "2022-09-16T17:18:27+00:00"^^xsd:dateTime;
pav:createdBy orcid:0000-0003-4727-9435 .
}